Igor L. Gomes-Santos

Igor L. Gomes-Santos

Auto-generated profile, based on publicly available information

Igor L. Gomes-Santos

Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JIJoao Incio
Joao Incio
JLJennifer A. Ligibel
Jennifer A. Ligibel
DMDaniel T. McManus
Daniel T. McManus
PSPriya Suboj
Priya Suboj
KJKeehoon Jung
Keehoon Jung
RJRakesh K. Jain
Rakesh K. Jain
Targeting IL-6 and potentially FGF-2 overcomes resistance to anti-VEGF therapy in breast cancer.

10 April 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
IGIgor L. Gomes-Santos
Igor L. Gomes-Santos
ZAZohreh Amoozgar
Zohreh Amoozgar
AKAshwin S. Kumar
Ashwin S. Kumar
WHWilliam W. Ho
William W. Ho
KRKangsan Roh
Kangsan Roh
DFDai Fukumura
Dai Fukumura
The mechanisms behind the antitumor effects of exercise training (ExTr) are not fully understood. Using mouse models of established breast cancer, we examined here the causal role of CD8+ T cells in the benefit acquired from ExTr in tumor control, as well as the ability of ExTr to improve immunotherapy responses. We implanted E0771, EMT6, MMTV-PyMT, and MCa-M3C breast cancer cells orthotopically in wild-type or Cxcr3−/− female mice and initiated intensity-controlled ExTr sessions when tumors reached approximately 100 mm3. We characterized the tumor microenvironment (TME) using flow cytometry, transcriptome analysis, proteome array, ELISA, and immunohistochemistry. We used antibodies against CD8+ T cells for cell depletion. Treatment with immune checkpoint blockade (ICB) consisted of anti–PD-1 alone or in combination with anti–CTLA-4. ExTr delayed tumor growth and induced vessel normalization, demonstrated by increased pericyte coverage and perfusion and by decreased hypoxia. ExTr boosted CD8+ T-cell infiltration, with enhanced effector function. CD8+ T-cell depletion prevented the antitumor effect of ExTr. The recruitment of CD8+ T cells and the antitumor effects of ExTr were abrogated in Cxcr3−/− mice, supporting the causal role of the CXCL9/CXCL11–CXCR3 pathway. ExTr also sensitized ICB-refractory breast cancers to treatment. Our results indicate that ExTr can normalize the tumor vasculature, reprogram the immune TME, and enhance the antitumor activity mediated by CD8+ T cells via CXCR3, boosting ICB responses. Our findings and mechanistic insights provide a rationale for the clinical translation of ExTr to improve immunotherapy of breast cancer.

1 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WHWilliam W. Ho
William W. Ho
IGIgor L. Gomes-Santos
Igor L. Gomes-Santos
SAShuichi Aoki
Shuichi Aoki
MDMeenal Datta
Meenal Datta
KKKosuke Kawaguchi
Kosuke Kawaguchi
RJRakesh K. Jain
Rakesh K. Jain
Significance: Immune checkpoint blockade (ICB) has been efficacious in several cancer types. However, mismatch repair–proficient (pMMR) metastatic colorectal cancer (CRC), ∼95% of total metastatic CRC cases, typically does not respond to ICB. Here, we show that orthotopic liver metastasis mouse models of pMMR CRC cell lines are unresponsive to ICB and recapitulate the resistance of human disease, unlike subcutaneous tumors of the same cell lines. We also show that just like the human disease, orthotopic pMMR CRC liver metastases have a paucity of T cells and dendritic cells, and that treatment with Flt3L sensitizes the liver metastases to ICB. Our findings highlight that orthotopic tumor models, and not subcutaneous models, should be used for preclinical studies of cancer immunotherapy.

24 May 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NTNilesh P Talele
Nilesh P Talele
HKHeena Kumra
Heena Kumra
IGIgor L Gomes-Santos
Igor L Gomes-Santos
WHWilliam W Ho
William W Ho
PAPatrik Andersson
Patrik Andersson
RJRakesh K Jain
Rakesh K Jain
Background Immune checkpoint blockers (ICBs) have revolutionized cancer therapy, yet they remain largely ineffective in treating pancreatic ductal adenocarcinoma (PDAC). Moreover, ICBs can cause severe immune-related adverse events (irAEs), including fatal cardiac toxicity. Finally, obesity is a risk factor in PDAC that may differentially modulate ICB efficacy in a malignancy-dependent manner. Methods We investigated the mechanisms underlying irAEs induced by dual ICB therapy and sought to identify strategies to mitigate them while improving ICB efficacy in the obese setting. To this end, we used a clinically relevant mouse model that integrated key features of human PDAC: (1) high-fat diet-induced obesity, (2) an orthotopic PDAC, and (3) a therapeutic regimen combining chemotherapy (FOLFIRINOX) with ICBs (α-programmed cell death protein-1 + α-cytotoxic T-lymphocyte associated protein-4 antibodies). Results Obese mice developed cardiac irAEs and had elevated serum interleukin (IL)-1β levels after chemoimmunotherapy. IL-1β blockade not only prevented myocarditis and reduced cardiac fibrosis but also enhanced the antitumor efficacy of the combination of chemotherapy plus dual ICB therapy and significantly improved the overall survival of PDAC-bearing obese mice. Conclusions Our findings provide the rationale and compelling data to test a Food and Drug Administration-approved anti-IL-1β antibody in combination with chemotherapy and dual ICB therapy in patients with pancreatic cancer with obesity.

2 March 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TCTassia S. R. da Costa
Tassia S. R. da Costa
UUUrsula Urias
Ursula Urias
MNMarcelo V. Negrao
Marcelo V. Negrao
CJCamila P. Jordão
Camila P. Jordão
CPClévia S. Passos
Clévia S. Passos
CNCarlos E. Negrao
Carlos E. Negrao
Background: Patients treated for breast cancer have a high incidence of cardiovascular complications. In this study, we evaluated the impact of breast cancer on cardiac function and cardiomyocyte Ca 2+ ‐handling protein expression. We also investigated whether exercise training (ET) would prevent these potential alterations. Methods and Results: Transgenic mice with spontaneous breast cancer (mouse mammary tumor virus–polyomavirus middle T antigen [MMTV‐PyMT+], n=15) and littermate mice with no cancer (MMTV‐PyMT−, n=14) were studied. For the ET analysis, MMTV‐PyMT+ were divided into sedentary (n=10) and exercise‐trained (n=12) groups. Cardiac function was evaluated by echocardiography with speckle‐tracking imaging. Exercise tolerance test was conducted on a treadmill. Both studies were performed when the tumor became palpable and when it reached 1 cm 3 . After euthanasia, Ca 2+ ‐handling protein expression (Western blot) was evaluated. Exercise capacity was reduced in MMTV‐PyMT+ compared with MMTV‐PyMT− ( P interaction =0.031). Longitudinal strain ( P group <0.001) and strain rate ( P group =0.030) were impaired. Cardiomyocyte phospholamban was increased ( P =0.011), whereas phospho‐phospholamban and sodium/calcium exchanger were decreased ( P =0.038 and P =0.017, respectively) in MMTV‐PyMT+. No significant difference in sarcoplasmic or endoplasmic reticulum calcium 2 ATPase (SERCA2a) was found. SERCA2a/phospholamban ratio was reduced ( P =0.007). ET was not associated with increased exercise capacity. ET decreased left ventricular end‐systolic diameter ( P group =0.038) and end‐diastolic volume ( P group =0.026). Other morphological and functional cardiac parameters were not improved by ET in MMTV‐PyMT+. ET did not improve cardiomyocyte Ca 2+ ‐handling protein expression. Conclusions: Breast cancer is associated with decreased exercise capacity and subclinical left ventricular dysfunction in MMTV‐PyMT+, which is at least partly associated with dysregulation of cardiomyocyte Ca 2+ handling. ET did not prevent or reverse these changes.